BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 18, 2002
View Archived Issues
MedImmune's FluMist Vaccine Recommended By FDA Panel
By dropping children younger than 5 from its label, MedImmune Inc. was able to convince an FDA panel of experts that the intranasal influenza vaccine FluMist is safe and efficacious in people ages 5 to 49. (BioWorld Today
Read More
Corixa's Bexxar Appears Headed For Approval After ODAC Meeting
Read More
How Botulinum's Muscle Paralysis Mechanism Combines Light, Heavy Chains In Close Molecular Embrace
Read More
Pozen Submits NDA To FDA Seeking Approval Of MT 300
Read More
Versicor Starts Phase III Trials Of Dalbavancin For Infections
Read More
Targeted Genetics Continues Cutbacks To Conserve Cash
Read More
Other News To Note
Read More